PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: PIPELINE ANALYSIS PART 06: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 07: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 08: MARKET SEGMENTATION BY APPLICATION • Segmentation by application • Comparison by application • Oncology – Market size and forecast 2017-2022 • Immunology – Market size and forecast 2017-2022 • Hematology – Market size and forecast 2017-2022 • Others – Market size and forecast 2017-2022 • Market opportunity by application PART 09: MARKET SEGMENTATION BY ORIGIN OF MONOCLONAL ANTIBODIES • Segmentation by origin of monoclonal antibodies • Murine antibodies • Human antibodies • Humanized antibodies • Chimeric antibodies PART 10: CUSTOMER LANDSCAPE PART 11: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Market opportunity PART 12: DECISION FRAMEWORK PART 13: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 14: MARKET TRENDS • Increasing cases of diseases like cancer and immunological disorders • Rise in the number of companies venturing into the monoclonal antibodies space • Growing pricing pressure in the monoclonal antibodies segment PART 15: VENDOR LANDSCAPE • Overview • Landscape disruption PART 16: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AbbVie • Amgen • Johnson & Johnson • Merck PART 17: APPENDIX • List of abbreviations Exhibit 01: Parent market Exhibit 02: Global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Monoclonal antibodies in the pipeline Exhibit 06: Market definition – Inclusions and exclusions checklist Exhibit 07: Market size 2017 Exhibit 08: Validation techniques employed for market sizing 2017 Exhibit 09: Global monoclonal antibodies market – Market size and forecast 2017-2022 ($ bn) Exhibit 10: Global monoclonal antibodies market – Year-over-year growth 2018-2022 (%) Exhibit 11: Five forces analysis 2017 Exhibit 12: Five forces analysis 2022 Exhibit 13: Bargaining power of buyers Exhibit 14: Bargaining power of suppliers Exhibit 15: Threat of new entrants Exhibit 16: Threat of substitutes Exhibit 17: Threat of rivalry Exhibit 18: Market condition – Five forces 2017 Exhibit 19: Global monoclonal antibodies market by application – Market share 2017-2022 (%) Exhibit 20: Comparison by application Exhibit 21: List of monoclonal antibodies approved by FDA/European Medicines Agency post 2015 Exhibit 22: Oncology – Market size and forecast 2017-2022 ($ bn) Exhibit 23: Oncology – Year-over-year growth 2018-2022 (%) Exhibit 24: Sales of monoclonal antibodies in oncology ($ mn) Exhibit 25: Immunology – Market size and forecast 2017-2022 ($ bn) Exhibit 26: Sales of monoclonal antibodies for immunology ($ mn) Exhibit 27: Immunology – Year-over-year growth 2018-2022 (%) Exhibit 28: Hematology – Market size and forecast 2017-2022 ($ bn) Exhibit 29: Hematology – Year-over-year growth 2018-2022 (%) Exhibit 30: Others – Market size and forecast 2017-2022 ($ bn) Exhibit 31: Sales of monoclonal antibodies in the others segment ($ mn) Exhibit 32: Others – Year-over-year growth 2018-2022 (%) Exhibit 33: Market opportunity by application Exhibit 34: Customer landscape Exhibit 35: Global monoclonal antibodies market by geography – Market share 2017-2022 (%) Exhibit 36: Regional comparison Exhibit 37: Americas – Market size and forecast 2017-2022 ($ bn) Exhibit 38: Americas – Year-over-year growth 2018-2022 (%) Exhibit 39: Top 3 countries in Americas Exhibit 40: EMEA – Market size and forecast 2017-2022 ($ bn) Exhibit 41: EMEA – Year-over-year growth 2018-2022 (%) Exhibit 42: Top 3 countries in EMEA Exhibit 43: APAC – Market size and forecast 2017-2022 ($ bn) Exhibit 44: APAC – Year-over-year growth 2018-2022 (%) Exhibit 45: Top 3 countries in APAC Exhibit 46: Market opportunity Exhibit 47: Vendor landscape Exhibit 48: Landscape disruption Exhibit 49: Vendor classification Exhibit 50: Market positioning of vendors Exhibit 51: AbbVie: An overview Exhibit 52: AbbVie – Business segments Exhibit 53: AbbVie – Organizational developments Exhibit 54: AbbVie – Geographic focus Exhibit 55: AbbVie – Segment focus Exhibit 56: AbbVie – Key offerings Exhibit 57: Amgen: An overview Exhibit 58: Amgen – Business segments Exhibit 59: Amgen – Organizational developments Exhibit 60: Amgen – Geographic focus Exhibit 61: Amgen – Segment focus Exhibit 62: Amgen – Key offerings Exhibit 63: Johnson & Johnson: An overview Exhibit 64: Johnson & Johnson – Business segments Exhibit 65: Johnson & Johnson – Organizational developments Exhibit 66: Johnson & Johnson – Geographic focus Exhibit 67: Johnson & Johnson – Segment focus Exhibit 68: Johnson & Johnson – Key offerings Exhibit 69: Merck: An overview Exhibit 70: Merck – Business segments Exhibit 71: Merck – Organizational developments Exhibit 72: Merck – Geographic focus Exhibit 73: Merck – Segment focus Exhibit 74: Merck – Key offerings    

AbbVie Amgen Johnson & Johnson Merck